Literature DB >> 18187660

A dynamic prognostic model to predict survival in post-polycythemia vera myelofibrosis.

Francesco Passamonti1, Elisa Rumi, Marianna Caramella, Chiara Elena, Luca Arcaini, Emanuela Boveri, Cecilia Del Curto, Daniela Pietra, Laura Vanelli, Paolo Bernasconi, Cristiana Pascutto, Mario Cazzola, Enrica Morra, Mario Lazzarino.   

Abstract

Post-polycythemia vera myelofibrosis (post-PV MF) is a late evolution of PV. In 647 patients with PV, we found that leukocytosis leukocyte count>(15x10(9)/L) at diagnosis is a risk factor for the evolution of post-PV MF. In a series of 68 patients who developed post-PV MF, median survival was 5.7 years. Hemoglobin level less than 100 g/L (10 g/dL) at diagnosis of post-PV MF was an independent risk factor for survival. The course of post-PV MF, however, is a dynamic process that implies a progressive worsening of clinical parameters. Using a multivariate Cox proportional hazard regression with time-dependent covariates, we found that a dynamic score based on hemoglobin level less than 100 g/L (10 g/dL), platelet count less than 100x10(9)/L, and leukocyte count more than 30x10(9)/L is useful to predict survival at any time from diagnosis of post-PV MF. The resulting hazard ratio of the score was 4.2 (95% CI: 2.4-7.7; P<.001), meaning a 4.2-fold worsening of survival for each risk factor acquired during follow up. In conclusion, leukocytosis at diagnosis of PV is a risk factor for evolution in post-PV MF. A dynamic score based on hemoglobin level, and platelet and leukocyte count predicts survival at any time from diagnosis of post-PV MF.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18187660     DOI: 10.1182/blood-2007-11-121434

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  32 in total

1.  Red cell mass measurement in patients with clinically suspected diagnosis of polycythemia vera or essential thrombocythemia.

Authors:  Alberto Alvarez-Larrán; Agueda Ancochea; Anna Angona; Carme Pedro; Francesc García-Pallarols; Luz Martínez-Avilés; Beatriz Bellosillo; Carlos Besses
Journal:  Haematologica       Date:  2012-06-11       Impact factor: 9.941

2.  Clinical relevance of JAK2 (V617F) mutant allele burden.

Authors:  Francesco Passamonti; Elisa Rumi
Journal:  Haematologica       Date:  2009-01       Impact factor: 9.941

3.  Advanced forms of MPNs are accompanied by chromosomal abnormalities that lead to dysregulation of TP53.

Authors:  Bridget K Marcellino; Ronald Hoffman; Joseph Tripodi; Min Lu; Heidi Kosiorek; John Mascarenhas; Raajit K Rampal; Amylou Dueck; Vesna Najfeld
Journal:  Blood Adv       Date:  2018-12-26

Review 4.  Quality of life in MPN comes of age as a therapeutic target.

Authors:  Robyn M Scherber; Holly L Geyer; Ruben A Mesa
Journal:  Curr Hematol Malig Rep       Date:  2014-12       Impact factor: 3.952

5.  Driver mutations' effect in secondary myelofibrosis: an international multicenter study based on 781 patients.

Authors:  F Passamonti; B Mora; T Giorgino; P Guglielmelli; M Cazzola; M Maffioli; A Rambaldi; M Caramella; R Komrokji; J Gotlib; J J Kiladjian; F Cervantes; T Devos; F Palandri; V De Stefano; M Ruggeri; R Silver; G Benevolo; F Albano; D Caramazza; E Rumi; M Merli; D Pietra; R Casalone; T Barbui; L Pieri; A M Vannucchi
Journal:  Leukemia       Date:  2016-11-25       Impact factor: 11.528

6.  The International Prognostic Scoring System does not accurately discriminate different risk categories in patients with post-essential thrombocythemia and post-polycythemia vera myelofibrosis.

Authors:  Juan-Carlos Hernández-Boluda; Arturo Pereira; Montse Gómez; Concepción Boqué; Francisca Ferrer-Marín; José-María Raya; Valentín García-Gutiérrez; Ana Kerguelen; Blanca Xicoy; Pere Barba; Jesús Martínez; Elisa Luño; Alberto Alvarez-Larrán; Joaquín Martínez-López; Elisa Arbelo; Carles Besses
Journal:  Haematologica       Date:  2014-01-31       Impact factor: 9.941

Review 7.  SOHO State-of-the-Art Update and Next Questions: MPN.

Authors:  Prithviraj Bose; Jason Gotlib; Claire N Harrison; Srdan Verstovsek
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2018-01

8.  Discrepancies of applying primary myelofibrosis prognostic scores for patients with post polycythemia vera/essential thrombocytosis myelofibrosis.

Authors:  Krisstina Gowin; Maria Coakley; Heidi Kosiorek; Ruben Mesa
Journal:  Haematologica       Date:  2016-06-27       Impact factor: 9.941

Review 9.  Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms.

Authors:  Neha Bhagwat; Ross L Levine; Priya Koppikar
Journal:  Int J Hematol       Date:  2013-05-14       Impact factor: 2.490

Review 10.  Polycythemia Vera: An Appraisal of the Biology and Management 10 Years After the Discovery of JAK2 V617F.

Authors:  Brady L Stein; Stephen T Oh; Dmitriy Berenzon; Gabriela S Hobbs; Marina Kremyanskaya; Raajit K Rampal; Camille N Abboud; Kenneth Adler; Mark L Heaney; Elias J Jabbour; Rami S Komrokji; Alison R Moliterno; Ellen K Ritchie; Lawrence Rice; John Mascarenhas; Ronald Hoffman
Journal:  J Clin Oncol       Date:  2015-08-31       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.